Teon Therapeutics Inc. Alternatives & Competitors

12 companies similar to Teon Therapeutics Inc. — Teon is a clinical company targeting metabolic signaling pathways and pioneering...

ARTBIO

Channeling Energy. Changing Lives.

74 Series B $245.00M

Cambridge, United States

Biotechnology Health Care +2

MILAGEN, INC.

Advancing Health Care Through Diagnostics

3 Series B $4.04M

Health Care

NBE-Therapeutics AG

Next generation antibody drug conjugates

47 Series C

Basel, Switzerland

Biotechnology Health Care +1

Glycyx

Restoring immune response in cancer: reversing Opioid-Induced Immunodeficiency to enhance...

3 Series A $7.10M

San Francisco, United Sta...

Biopharma Biotechnology +1

Track all Teon Therapeutics Inc. competitors

Get real-time alerts when any of these companies raise funding, hire, or show growth signals.

See how it works

Prelude Therapeutics

Precision Oncology, Redefined.

126 Post Ipo Equity $147.00M

Wilmington, United States

Biopharma Biotechnology +2

TREOS BIO

Next generation off-the-shelf peptide cancer vaccines effective in broad patient populatio...

15 Convertible Note $22.00M

London, United Kingdom

Biotechnology Health Care +1

Pathios Therapeutics

Using human genetics to transform cancer outcomes

24 Series B $34.37M

United Kingdom

Biotechnology Health Care +1

Avacta Therapeutics

Expanding the reach of highly potent cancer therapies with the pre|CISION® platform.

44 Post Ipo Equity

London, United Kingdom

Biotechnology Health Care +1

Arcellx

Arcellx is a clinical-stage biotechnology company based in Redwood City, California

224 Acquired $8.43B

Redwood City, United Stat...

Biopharma Biotechnology +3

ImmunoGen

Focusing on core therapeutic areas such as immunology, oncology, neuroscience, eye care, a...

34 Acquired $681.30M

Biotechnology Health Care +1

Siren Biotechnology

Universal AAV immuno-gene therapy for cancer

9 Seed $23.60M

San Francisco, United Sta...

Biotechnology

Clasp Therapeutics

Pioneering precise immuno-oncology with next-gen T cell engagers targeting specific tumor...

42 Series A $150.00M

About Teon Therapeutics Inc.

Teon is a clinical company targeting metabolic signaling pathways and pioneering the development of GPCR therapies

Services

Development of oncology therapeutic drugs, Clinical trials for cancer drug efficacy, Research in metabolic and GPCR pathways

Target Customers

Cancer patients with solid tumors, Oncologists and medical professionals, Healthcare institutions and research organizations

Taxonomy

Clinical-stage Company, Metabolic Signaling Pathways, GPCR Therapies, GPCR Immunotherapies, Difficult-to-treat Cancers, Biopharmaceutical Company, Cancer Patient-focused, Small Molecule Development, Immunosuppressive Signaling Pathways, Tumor Microenvironment, Cancer-promoting Pathways, A2BR-specific Antagonist, Phase 1b Trials

Business Model

B2B

Revenue Model

Licensing, Product Sales, Value Based Pricing

Frequently Asked Questions

Top alternatives to Teon Therapeutics Inc. include ARTBIO, MILAGEN, INC., NBE-Therapeutics AG, Glycyx, Prelude Therapeutics. These companies serve similar markets and are frequently compared.

Bounce Watch tracks 12 companies similar to Teon Therapeutics Inc. based on industry overlap, target customers, and business model.

Teon is a clinical company targeting metabolic signaling pathways and pioneering the development of GPCR therapies

Don't just read about them. Follow them.

BounceWatch watches Teon Therapeutics Inc. and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.

See how it works

Explore Related

Teon Therapeutics Inc. Profile ARTBIO Alternatives MILAGEN, INC. Alternatives NBE-Therapeutics AG Alternatives All Companies All Signals Trend Reports

Compiled from the BounceWatch company index. We last looked at Teon Therapeutics Inc. on 11 Mar 2026. The 12 companies listed here were last checked between 27 Nov 2025 and 3 Jul 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.